Company profile
Satellos Bioscience Inc.
NASDAQ:MSLEBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06867107 | phase2 | enrolling_by_invitation | 2025-08-20 | 2026-08-30 | Satellos Bioscience, Inc. | An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 |
| NCT06565208 | — | completed | 2024-08-21 | 2025-04-28 | Satellos Bioscience, Inc. | First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort |
| NCT07287189 | phase2 | recruiting | 2025-12-08 | 2027-03-31 | Satellos Bioscience, Inc. | Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients |
FDA applications (0)
No records yet.